Physician profile
Yvette Ortiz
NPI 1497722078
$3,505.99
in general payments reported to CMS, 2019-2025
26 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.87 · 2022: $96.94 · 2024: $1,809 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.81 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $470.47 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Boston Scientific Corporation | $447.54 | 2022-2025 | Watchman Access System, Watchman Flx |
| Exact Sciences Corporation | $272.04 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $250.91 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.01 | 2024-2025 | |
| Amgen INC. | $159.90 | 2024-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $145.16 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.29 | 2025 | Farxiga, Airsupra, Breztri |
| E.R. Squibb & Sons, L.L.C. | $109.26 | 2024-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.10 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $98.10 | 2024 | Xarelto |
| Heartflow, INC. | $90.42 | 2024 | |
| Esperion Therapeutics, INC. | $76.63 | 2024-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $66.18 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.31 | 2025 | Veozah |
| Currax Pharmaceuticals LLC | $64.36 | 2024-2025 | Contrave |
| Merz North America, INC. | $48.87 | 2019 | |
| Glaxosmithkline, LLC. | $41.26 | 2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $39.80 | 2024-2025 | Verquvo, Capvaxive |
| Cvrx, INC. | $28.89 | 2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $26.12 | 2024 | Onpattro |
| Abbvie INC. | $24.91 | 2025 | |
| Eisai INC. | $23.37 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.63 | 2025 | Rexulti |
| Insightec,INC | $17.65 | 2025 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.